Canada signs deal with Novovax to get 76 million doses of COVID-19 vaccine
OTTAWA -- The federal government has a deal with a third vaccine developer to get access to an experimental COVID-19 vaccine as early as next spring.
Prime Minister Justin Trudeau is in Montreal this morning where he is set to announce details of the agreement with Maryland-based biotechnology company Novovax.
The contract promises to secure for Canadians 76 million doses of Novovax's vaccine, which is currently in preliminary trials in the United States and Australia.
That would be enough to deliver two doses to almost every Canadian.
This is the third such deal Canada has made with COVID-19 vaccine developers, adding Novovax to similar arrangements made with Pfizer and Moderna earlier this month.
All vaccines remain in clinical trials and must first be deemed safe by the developers and then approved by Health Canada for use here before any Canadians will be vaccinated.
- Canada signs deals with Pfizer, Moderna to get doses of COVID-19 vaccines
- Canada signs deals with two suppliers for potential COVID-19 vaccines
- Feds pledge $440 million to join international vaccine program
- Feds enter agreement for 72 million doses of adjuvanted COVID-19 vaccine
- Canadian company urges human trials after COVID-19 vaccine results in mice
- New rules regarding children in leash-free zones and smoking in parks are now in effect in Mississauga
- PHOTOS: New platform and pavilion now open at a Mississauga GO Station
- Staff member tests positive for COVID-19 at Mississauga retirement home
- House of the Week: $3.8 mil Sheridan home luxurious features
- All COVID-19 cases in Mississauga schools for the week of September 21 to 26